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RESEARCH ARTICLE
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Abstract
Myocardial ischemia can damage heart muscle and reduce the heart’s pumping
efficiency. This study used an ischemic swine heart model to investigate the
potential for gene electro transfer of a plasmid encoding vascular endothelial
growth factor for improving perfusion and, thus, for reducing cardiomyopathy
following acute coronary syndrome. Plasmid expression was significantly greater in
gene electro transfer treated tissue compared to injection of plasmid encoding
vascular endothelial growth factor alone. Higher gene expression was also seen in
ischemic versus non-ischemic groups with parameters 20 Volts (p,0.03), 40 Volts
(p,0.05), and 90 Volts (p,0.05), but not with 60 Volts (p,0.09) while maintaining a
pulse width of 20 milliseconds. The group with gene electro transfer of plasmid
encoding vascular endothelial growth factor had increased perfusion in the area at
risk compared to control groups. Troponin and creatine kinase increased across all
groups, suggesting equivalent ischemia in all groups prior to treatment.
Echocardiography was used to assess ejection fraction, cardiac output, stroke
volume, left ventricular end diastolic volume, and left ventricular end systolic
volume. No statistically significant differences in these parameters were detected
during a 2-week time period. However, directional trends of these variables were
interesting and offer valuable information about the feasibility of gene electro
transfer of vascular endothelial growth factor in the ischemic heart. The results
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demonstrate that gene electro transfer can be applied safely and can increase
perfusion in an ischemic area. Additional study is needed to evaluate potential
efficacy.
Introduction
Myocardial ischemia occurs when myocardial oxygen delivery fails to satisfy the
rate of myocardial oxygen consumption. Given the high metabolic demand of the
myocardium, ischemia can have immediate effects on the ability of the heart to
contract effectively. When ischemia persists, permanent heart damage may result
[1]. Current treatment for myocardial ischemia is directed at improving the
balance between oxygen delivery and consumption. In some pathological
conditions that lead to myocardial ischemia, only medication is necessary to
decrease the rate of myocardial oxygen consumption relative to the rate of
myocardial oxygen delivery. However, in cases of acute coronary syndrome, the
imbalance can be so abrupt and so severe that more aggressive therapy is
necessary. Traditionally, patients with suitable anatomies following atherosclerotic
changes can be treated with percutaneous catheter based interventions (PCI) or
with surgical coronary artery by-pass (CABG). These treatments aim to restore
adequate blood flow through the coronary arteries and, therefore, to deliver
adequate myocardial oxygen.
Unfortunately, the anatomy of some patients’ atherosclerotic disease limits the
potential for PCI and/or CABG to improve myocardial oxygen delivery to
ischemic areas of the heart [2]. Although mechanical ventricular assist devices and
cardiac transplant are possibilities at some time points, options are limited once
patients have progressed to end-stage heart failure. Currently, only transmyo-
cardial laser revascularization (TMLR) offers potential improvement in
myocardial oxygen delivery in the native heart in these patients. TMLR is thought
to work indirectly by up-regulating the expression of vascular endothelial growth
factor (VEGF) and promoting collateral neovascular growth, which improves
perfusion.
Gene therapy is an approach that has emerged as a potential method for
delivering angiogenic factors such as VEGF to the ischemic myocardium directly.
Adenoviral (Ad) delivery has provided useful and thought provoking results [3].
However, Ad-based vectors are limited because this approach may cause severe
tissue damage with large areas of interstitial inflammatory cell infiltration and
myocyte necrosis [3]. Currently, clinical trials are investigating the efficacy of
injecting naked DNA directly into the heart. Although the concept is promising, it
is unclear whether the level of expression achieved will be clinically effective.
Fortuin et al. reported clinical improvements in patients in a 1-year follow-up
study after direct myocardial gene transfer of VEGF-2 using naked plasmid DNA;
however, no angiographic evidence of angiogenesis was reported [4].
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Gene electro transfer (GET) is an approach that utilizes electric fields to
facilitate intracellular delivery of molecules [5, 6]. The controlled application of
electric pulses facilitates the entry of DNA by permeabilizing the cell membrane.
This approach has been successfully used in vivo to deliver plasmid DNA to
skeletal muscle [6] and to cardiac tissue [7, 8]. Previously, we and others
demonstrated that electro transfer could be used effectively to deliver plasmid
DNA directly to cardiac tissue in vivo [7–10]. We have further confirmed that
electro transfer is a viable approach for delivering plasmid DNA into cells of the
porcine heart in vivo. The GET parameters were selected based on the size and
structure of swine cardiac myocytes. We also determined a pulse length that could
be administered during the rising phase of the R wave of the electrocardiogram
(ECG), but concluded before the start of the T wave, while at the same time
providing significant gene expression. We previously demonstrated that
synchronizing the electric pulses to the rising phase of the R wave of the ECG
allowed for efficient administration of GET with minimal risk of fibrillating the
heart. [9].
Previously, we reported that various electrode configurations can be used to
facilitate gene delivery to the heart [10]. In this study, we used our custom-made
7 mm electrode and injected DNA at a concentration of 0.2 mg/100 ml. Using this
electrode, we evaluated in vivo delivery of a plasmid encoding vascular endothelial
growth factor (pVEGF) to the myocardium of the heart via varying field strengths.
VEGF is a potent mediator of angiogenesis [11–13]. Humans express alternately
spliced isoforms of VEGF-A varying from 121, 145, 165, 183, 189, to 206 amino
acids in length [12]. VEGF165 appears to be the most abundant and potent
isoform, followed by VEGF121 and VEGF189 [11–13]. VEGF has also been
associated with angiogenesis following myocardial infarction [14]. Gene therapy
approaches that have been utilized for treating cardiac ischemia have shown that
VEGF plays a role in angiogenesis [4, 15].
In the present study, we investigated the ability of GET to deliver pVEGF
effectively to the ischemic swine heart. We further evaluated the influence that this
approach had on the level of perfusion within the ischemic area of the heart. The
results obtained in this study demonstrate that GET is an effective tool for
delivering plasmid DNA to the heart. Delivery of pVEGF utilizing the appropriate




Seventy, adult, castrated male, domestic farm pigs weighing 31–47 kg were used
for this study. All swine were purchased as specific pathogen free (SPF) for
pseudorabies and brucellosis from a commercial swine vendor’s (Bellview Farms,
Smithville, Virginia) closed herds. All animals were given health examinations by
an ACLAM board certified veterinarian and were determined to be free of disease.
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In addition, all animals were processed on-site and were quarantined for a 7 day
acclimation period before any procedures were conducted. An ultrasound exam
was conducted on each animal’s heart to obtain baseline measures of cardiac
performance. Animals were housed in stainless steel runs, with three animals to a
room and one animal per run to allow socializing. The animal rooms were
maintained in accordance with the Guide for the Care and Use of Laboratory
Animals [16], including a 12:12-hour light cycle. Room temperature was
maintained at 15–17 C̊ with a relative humidity between 40–65%, and with 12–15
air changes hourly. Animals were feed Swine food (Teklad Swine Chow, no. 8753,
Madison, WI, USA) twice per day and provided water ad libitum via an automatic
watering system (Edstrom Industries, Waterford, WI, USA). Environment
enrichment included daily food treats, toys, and human interaction. This study
was conducted in an AAALAC-accredited facility and in compliance with the
Animal Welfare Act and other federal statutes and regulations pertaining to
animals [16]. All procedures outlined in this study were approved by Old
Dominion University’s animal care and use committee.
Plasmid
The plasmid utilized for these experiments was pVax1-hVEGF165 (pVEGF). The
plasmid was prepared commercially (Aldevron, Fargo, ND) and suspended to a
concentration of 2 mg/ml in sterile injectable saline. Each production of plasmid
was tested by Aldevron using a Limulus Amebocyte Lysate assay to assure
endotoxin levels were ,0.1 EU/mg plasmid.
Pre-surgical preparation
All animals were sedated by intramuscular administration of ketamine (20 mg/kg)
and diazepam (3–5 mg/kg). Sedation facilitated placement of catheters in veins of
both ears for all intravenous injections. Once the catheters were in place, the
animals were anesthetized with isoflurane through a nose mask. Once
anesthetized, each animal was intubated with a 5 or 6 French endotracheal tube
and placed on a ventilator.
Surgical preparation
Surgical preparation was reported previously [9]. Briefly, animals were placed in a
surgical plane of anesthesia by administering isoflurane at 2–3% with an oxygen
flow rate of 2 liters per minute. The lungs were ventilated (200–300 ml tidal
volume with 14–18 breaths per minute) using a BonAir mechanical ventilator
(DRE, Inc., Louisville, KY, USA). Animals were monitored constantly and the
level of isoflurane was adjusted as needed to maintain the animal in a surgical
plane of anesthesia. Additional preparation included shaving the ventral thorax
(chest) and using an initial surgical scrub. The animals were placed in a dorsal
recumbence position on a heated surgical table. ECG leads were attached and the
Gene Transfer in the Ischemic Swine Heart
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ECG R wave was monitored for the purpose of delivering the electric field. The
chest was once again scrubbed with 70% alcohol and chlorhex-Q.
Surgical procedure
A sterile surgical field was established by draping the chest. The skin and
underlying soft tissues were divided sharply at the midline. A striker saw was used
to open the sternum, and a standard sternal retractor was used to expose the
pericardium, which was opened from the diaphragmatic reflection to the level of
the atrium. Amiodarone (300 mg) was given intravenously (i.v.) and a lidocaine
drip (50–75 mg/kg/min, i.v.) was used to provide protection from arrhythmia.
ECG and blood pressure were monitored continuously using a SurgiVet monitor
(Smiths Medical Dublin, OH). A blood pressure cuff was placed around the right
hind limb to continuously assess blood pressure. Body temperature was
continuously measured by placing a temperature probe in the rectum, with the
probe also being connected to the SurgiVet monitor. Blood gases were measured
using a Vetstat Electrolyte and Blood Gas Analyzer (IDEXX, Westbrook, Maine).
Creation of Ischemia
Partial occlusion of blood flow through the left anterior descending coronary
artery (LAD) was achieved by placing a 4-0 silk suture around the LAD
approximately 3–4 cm from the apex of the left ventricle. A 20 gauge blunt needle
was placed over the vessel and the suture was tied securely around the shaft of the
blunt needle. Once the suture knot was in place, the blunt needle was removed,
creating a partially occluded coronary stenosis. Four silk sutures were placed 2 cm
apart on the anterior wall of the left ventricle both to mark the location of each
plasmid injection and to define the treatment area of ischemic myocardium,
which was supplied by the stenotic LAD. Assessment of coronary perfusion of this
treatment region was performed using the SPY Intraoperative Perfusion
Assessment System. (See ‘‘SPY Analysis’’ below).
Treatment procedure
The treatment protocol was initiated after occlusion of the LAD. Fig. 1 shows a
schematic of the treatment procedure. Animals were divided into three basic
treatment groups: no treatment, injection of pVEGF without GET, or injection of
pVEGF with GET. We had established previously that the pulses could be
administered without causing fibrillation by synchronizing the electric pulses to
the rising edge of the R wave, with the pulse being completed before the start of
the T wave [9]. Therefore, prior to initiating the pulsing protocol, the ECG for
each animal was analyzed to delineate the rising phase of the R wave. The
electrode applicator contained a central injection port, which allowed the
injection needle to be inserted to a controlled depth. To target delivery to the
myocardium, a spacer that allowed insertion of the injection needle to 3.5 mm
Gene Transfer in the Ischemic Swine Heart
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was used. The applicator contained 4 penetrating electrodes spaced 5 mm apart
and 7 mm long to target delivery to the myocardium of the left ventricle [8].
Several GET parameters were tested. For those animals receiving GET with
pVEGF, the following procedure was implemented. The pulse width was constant
at 20 milliseconds, while the applied electric field was varied. The delivery
parameters included 20 V, 40 V, 60 V or 90 V. A total of four sites, each 2 cm
apart, on the anterior wall of the left ventricle of the porcine heart were injected
with plasmid and exposed in vivo to the applied electric fields (Fig. 1). The
applicator forms a 565 mm area. This electrode was designed to facilitate the
administration of four pulses in each of two perpendicular directions [8]. For
animals receiving only an injection of pVEGF without GET (injection only, or
IO), the procedure was the same in terms of the placement of applicator and DNA
injection, except that no electric pulses were administered. For the no treatment
group (sham), we followed the same procedure except that the applicator was not
used, no pVEGF was injected, and GET was not performed.
For all animals, after the last site was treated, the sternum was closed with
surgical steel monofilament 18-inch surgical needles. All other incisions were
closed with Vicryl plus-antibacterial suture (3.5 metric). The surgical area was
Fig. 1. Sequence for administration of therapy. A) The heart was exposed as described in the Methods section under ‘‘surgical procedure’’. B) The left
anterior descending coronary artery is ligated with a permanent suture (arrow) and a SPY image is collected to visualize change in perfusion. C) Sutures are
placed to designate the treatment sites. D) Sequence of treatment, applicator containing 4 electrodes and injection port is placed at the treatment site
marked by suture; 100 ml of plasmid solution at a concentration of 2 mg/ml is injected; 8 pulses are administered. Procedure is repeated for the other 3 sites.
doi:10.1371/journal.pone.0115235.g001
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bandaged using sterile TelFa non- adherent pads and secured by wrapping the
chest with Vet Wrap to protect the incision from contamination. Postoperatively,
all animals remained in the operating room under constant observation until
extubation. Analgesics for pain relief included Carprofen, given intramuscular
(IM) just prior to completion of the surgical procedure (4 mg/kg) and once daily
(100 mg tablets by mouth) for 3 days. Buprenorphine (0.1 mg/kg) was also given
IM once after the animal was extubated and breathing comfortably on its own.
SPY Analysis
The SPY Intraoperative Perfusion Assessment System (Novadaq Technologies,
Inc, Bonita Springs, FL) was used to image, capture, and view dynamic
fluorescence images of the area of myocardium at risk. Fluorescent intensity was
measured in arbitrary units. Changes in the intensity of fluorescence have been
Fig. 2. Intra-cardiac delivery of pVax1-hVEGF165. The duration of intra-cardiac delivery of pVax1-hVEGF165
was 20 milliseconds at varying voltages. Plasmid expression was significantly greater in the ischemic hearts
with parameters 20 milliseconds; 20 V (p,0.03 non- ischemic versus ischemic), 20 milliseconds; 40 V
(p,0.05 non- ischemic versus ischemic), and 20 milliseconds; 90 V (p,0.05 non- ischemic versus ischemic),
but not with the 20 milliseconds; 60 V parameter (p,0.09 non- ischemic versus ischemic). The non-treated
hearts had significantly less expression (p,0.002) than the hearts treated with injection only.
doi:10.1371/journal.pone.0115235.g002
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shown to be directly related to changes in perfusion [17]. Assessment of
fluorescent intensity was performed on the treatment area before and after
ischemia was induced by partial LAD stenosis and again 2 weeks post infarction.
To produce an image, an intravenous injection of isocyanogreen (ICG) was given
at 10 ml/kg. ICG is a sterile, water soluble, tricarbocyanine dye. Before injection,
ICG was reconstituted using the aqueous solvent provided with the ICG.
Cardiac Enzyme Assays
Cardiac troponin-1 and creatine kinase were measured using commercially
available kits. The cardiac enzyme troponin-1 was measured using a Pig Cardiac
Fig. 3. Expression of pVax1-hVEGF165. pVEGF expression was analyzed over a two week period at
48 hours, 7 days and 14 days. Peak expression was observed at 48 hours in all ischemic tissues at all
parameters except 20 milliseconds; 60 V. VEGF expression was significantly greater in the 20 milliseconds;
60 V parameter 14 days after ischemia was produced.
doi:10.1371/journal.pone.0115235.g003
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Troponin-I, K-ASSAY Pig Cardiac Troponin-I, High Sensitive ELISA (Kamiya
Biomedical Company, Seattle, WA) according to manufacturer’s instructions.
Creatine kinase was measured using a Pig CK-MM ELISA (Kamiya Biomedical
Company, Seattle, WA) also according to manufacturer’s instructions. Three
milliliters of whole blood were collected immediately after chest closure and
1 hour, 3 hours, 1 day, 2 days, 4 days and 14 days post procedure; blood samples
were centrifuged and plasma removed and frozen at 280 C̊ until running
troponin and creatine kinase ELISAs. Coated wells of the kits were loaded with
100 ml of calibrator or diluted samples. All samples were run in duplicate. The
optical density was read at 450 nm with a microtiter plate reader within 5 minutes
of adding the stop solution.
Echocardiography
All animals were sedated with diazepam (50 mg, PO) and ketamine (20 mg/kg,
IM), to alleviate anxiety before being placed under general anesthesia (isoflurane
in oxygen). A left side, short axis, left ventricular parasternal electrocardiographic
approach was used to analyze selected aspects of heart function. A 180 Plus
Sonosite ultrasound machine (National Ultrasound, Duluth, Georgia) with a 7 Hz
transducer was used to perform two dimensional and M-Mode echocardiography.
Analysis software, which included a cardiac package, was used to quantitate
ejection fraction (EF), cardiac output (CO), left ventricular end diastolic volume
(LVEDV), left ventricular end systolic volume (LVESV) and stroke volume (SV).
The software in this machine uses Teicholz measures obtained from the M mode
to calculate the variables analyzed. Electrocardiography was performed at three
different time points as follows: before the LAD was partially occluded, following
closure of the chest cavity (post myocardial infarction (MI)), and 14 days post
infarction.
Table 1. Fluorescent Intensity measurement using The SPY Elite Intraoperative Perfusion Assessment System.
GROUP
% Decrease In Fluorescent Intensity Immediately
Post- MI Compared to Pre-MI
% Decrease In Fluorescent Intensity 2 Weeks
Post-MI Compared to Pre-MI
No Treatment (n54) 86.8¡2.9 71¡22.2
pVEGF Injection Only (n54) 84.3¡10.5 64.3¡24.9
pVEGF +GETP (20 ms; 20 V) (n55) 82.8¡6.7 61.6¡16.3
pVEGF + GET (20 ms; 40 V) (n55) 83.6¡14.1 33.2¡16.9
pVEGF + GET (20 ms; 60 V) (n55) 87.2¡4.2 19.0¡42.9**
pVEGF + GET (20 ms; 90 V) (n55) 83.2¡6.7 51.2¡3.5
pVEGF 5 plasmid vascular endothelial growth factor.
**p,0.03 GET-pVEGF (20 milliseconds; 60 V) versus No Treatment or pVEGF Injection Only. ms 5 milliseconds, V 5 volts. Data stated as mean ¡ SD.
doi:10.1371/journal.pone.0115235.t001
Gene Transfer in the Ischemic Swine Heart
PLOS ONE | DOI:10.1371/journal.pone.0115235 December 29, 2014 9 / 23
Gene Transfer in the Ischemic Swine Heart
PLOS ONE | DOI:10.1371/journal.pone.0115235 December 29, 2014 10 / 23
Tissue Harvesting
Two, 7 or 14 days post MI, animals were placed under a surgical plane of
anesthesia and the sternum re-opened. For animals 2 or 7 days post MI, the heart
was exposed; the animal was euthanized; and the heart was removed. For animals
14 days post MI, the heart was exposed; the SPY procedure was performed as
described above; the animal was then euthanized and the heart removed. For all
animals, once the heart was removed, areas of the left ventricle defined by the
sutures were dissected and frozen at 280 C̊ until analysis for the presence of
vascular endothelial growth factor (VEGF).
VEGF Expression
VEGF expression was measured using the Quantikine Human VEGF
Immunoassay ELISA kit (R&D Systems, Inc. Minneapolis, MN 55413). This is a
solid phase ELISA designed to measure VEGF165 levels in the supernatant of the
heart. It contains Sf 21-expressed recombinant human VEGF165 and antibodies
raised against the recombinant protein. The kit includes plates pre-coated with a
monoclonal antibody specific for VEGF. Tissue samples were homogenized and
standards and samples were pipetted into the wells. Any VEGF present was bound
by the immobilized antibody. After washing away any unbound substances, an
enzyme-linked polyclonal antibody specific for VEGF was added to the wells.
Following a wash to remove any unbound antibody-enzyme reagent, a substrate
solution was added to the wells, and color developed in proportion to the amount
of VEGF bound in the initial step. The color development was stopped and the
intensity of the color was measured.
Results
It should be noted that the echocardiographic results reported in this study were
obtained in male swine that were in a deep plane of anesthesia.
GET delivery of pVEGF to the beating heart
This procedure was performed following either partial occlusion of the LAD
(ischemic tissue) or without occlusion of the LAD (non-ischemic tissue). Each
animal had four treatment sites on the anterior surface of the left ventricle. All
GET parameters were kept constant (20 millisecond pulse width, 8 pulses and 5
millimeter electrode gap), except for the applied voltage. Four different voltages
(20, 40, 60 and 90) were used to deliver pVEGF. After treatment, the animal was
Fig. 4. Ejection Fraction. Echocardiography was used to obtain levels of ejection fraction for pVEGF injection
only, sham and pVEGF +GET groups. A) Ejection fraction levels before MI, after the left anterior descending
artery (LAD) was occluded and 14 days post MI. B) Change in ejection fraction at 2 weeks when compared to
pre MI baseline. C) Change in ejection fraction at 2 weeks when compared to post MI baseline. There were no
statistically significant differences in EF between the groups.
doi:10.1371/journal.pone.0115235.g004
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returned to its housing facility for 48 hours. Expression levels of VEGF were
significantly greater if the plasmid was delivered by GET versus by DNA IO or
sham treatment (p,0.05). In addition, expression was significantly greater
(p,0.05) in ischemic hearts than in non-ischemic hearts when GET was
administered at 20 V (p,0.03), 40 V (p,0.05) and 90 V (p,0.05), but not with
the 60 V parameter (p,0.09). The non-ischemic hearts receiving only pVEGF and
no GET had significantly less gene expression (p,0.002) than did the hearts
treated with injection of plasmid and electroporation (Fig. 2).
We also investigated changes in pVEGF expression over time (Fig. 3) in the
ischemic and non-ischemic hearts. As was seen at 48 hours, expression was
significantly greater when the plasmid was delivered by GET versus DNA IO or
with sham treatment (p,0.05). When comparing the difference in expression
between delivery to ischemic versus non-ischemic tissue, pVEGF expression was
significantly greater in the ischemic hearts at the 48 hour time point in all
parameters except 60 V (20 V p,0.03, 40 V p,0.05 and 90 V p,0.03). At 14
days post-infarction, VEGF expression was significantly greater in the 20 V
(p,0.001), 40 V (p,0.03) and 60 V (p,0.0001), but not in the 90 V.
Analysis of Perfusion by SPY
The SPY Intraoperative Perfusion Assessment System was used to image, capture
and view fluorescence images for the visual assessment of fluorescent intensity of
the treatment area on the anterior myocardium. After partial occlusion of the mid
LAD, the drop in fluorescent intensity occurring in the ischemic portion of the left
ventricle was determined prior to initiation of treatment and immediately after
the LAD was partially occluded. A drop in fluorescent intensity is an indirect
marker that correlates directly with perfusion. The mean drop in intensity of
fluorescence from the pre-MI period to immediately after the MI was between 82–
87% (Table 1). Two weeks post MI and post treatment, the mean drop in
fluorescent intensity was between 19–71%. In the hearts treated with pVEGF +
GET, levels of improvement varied based on the GET parameters used (Table 1).
The largest improvement was observed when pVEGF was delivered with GET
administered at 60 V.
This result suggests that delivery with GET administered at 60 V was the most
appropriate. This observation also indicates that it may be important to have
elevated levels of expression in both ischemic and non-ischemic tissue. We draw
this conclusion because GET delivery of pVEGF administered at 60 V performed
in either ischemic or non-ischemic tissue achieved similar expression levels
Fig. 5. Cardiac Output. Echocardiography was used to obtain cardiac output measurements for pVEGF
injection only, sham and pVEGF +GET groups. A) Cardiac output levels before myocardial infarction, after the
left anterior descending artery (LAD) was occluded and 14 days post MI. B) Change in cardiac output at 2
weeks when compared to pre MI baseline. C) Change in cardiac output at 2 weeks when compared to post MI
baseline. There were no statistically significant differences in CO between the groups.
doi:10.1371/journal.pone.0115235.g005
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(except at Day 14). Therefore, this parameter was used to investigate effects of
pVEGF delivery on changes in echocardiography and in cardiac enzymes further.
Echocardiography
Echocardiography was performed with all animals under general anesthesia
(isoflurane and oxygen). It was used to assess ejection fraction (EF), cardiac
output (CO), stroke volume (SV), heart rate (HR) and left ventricular end
diastolic and systolic volumes (LVEDV and LVESV). Echocardiography was
performed on all animals before surgery, after partial occlusion of the LAD
coronary artery and closure of the chest cavity, and 14 days post MI at the left
ventricular mid-cavity level using the left side short axis parasternal view. The
myocardial infarction established a new baseline value. Changes in these
parameters were assessed by comparing the measurements taken at 2 weeks to the
baseline levels pre and post-MI.
In the GET treated group, EF was relatively stable. There was a decrease
immediately post-MI, but after two weeks, EF had returned close to baseline (pre-
MI) level (Fig. 4). The sham group had a decreased EF immediately post-MI, but
had a large increase compared to pre-MI baseline at 2 weeks. IO group had a
decreased EF immediately post-MI and did not recover (i.e., the EF level remained
reduced). There was a significant difference between the sham and the IO treated
animals (p,0.03).
Changes in CO for all three groups were similar. Immediately post-MI, all three
groups had a reduction in CO. Comparing 2 weeks vs immediately post-MI, there
was a 0.71 L/min increase in CO in the IO group, a 0.90 L/min increase in CO in
the sham group, and a 2.2 L/min increase in the plasmid + GET treated group two
weeks post infarct (Fig. 5). There were no significant differences between the
groups.
Measurements of HR at 2 weeks compared to pre-MI revealed minor changes,
with IO and GET groups showing a small decrease and sham showing a small
increase. Comparisons at 2 weeks with immediately post-MI revealed that HR
increased by 40 bpm in the IO group, by 45.5 bpm in the sham group, and by
64.4 bpm in the plasmid +GET group. There were no significant differences
between the groups (Fig. 6).
Two weeks post-MI, SV was slightly decreased in the IO group and increased in
the sham and GET groups when compared to pre-MI (Fig. 7). The increase was
higher in the GET group compared to the sham group. Stroke volume at 2 weeks
was higher than SV immediately post-MI for all three groups. GET group had the
Fig. 6. Heart Rate. Echocardiography was used to obtain heart rate for pVEGF injection only, sham and
pVEGF +GET groups. A) Heart rate before myocardial infarction, after the left anterior descending artery
(LAD) was occluded and 14 days post MI. B) Change in heart rate at 2 weeks when compared to pre MI
baseline. C) Change in heart rate at 2 weeks when compared to post MI baseline. There were no statistically
significant differences in HR between the groups.
doi:10.1371/journal.pone.0115235.g006
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highest increase while IO and sham had only a small increase. There were no
significant differences between the groups.
There was an increase in LVEDV from 19 ml post MI to 31 ml 2 weeks post MI
in the IO group, a decrease from 25 ml to 20 ml in the sham group, and an
increase from 27 ml to 34 ml in the plasmid +GET group. These changes did not
differ significantly (Fig. 8). There was an increase in LVESV from 7 ml
immediately post-MI to 12 ml 2 weeks post MI in the IO group, a decrease from
10 ml to 3 ml in the sham group, and an increase from 9 ml to 10 ml in the
plasmid +GET group (Fig. 9). There were no significant differences between the
groups.
Analysis of Cardiac Enzymes
Plasma cardiac troponin levels were elevated 1 day after partial occlusion of the
LAD in all animals (Table 2), suggesting adequate ischemic stimulus in all hearts.
However, in the pVEGF +GET group, troponin levels had returned to levels below
those observed immediately after the chest was closed. This was not observed in
the pVEGF only group or in the sham group. The increase in creatine kinase
(Table 2) was observed immediately after the chest was closed in all animals.
However, enzyme levels in the pVEGF +GET group were 80% lower by Day 14
post infarction compared to a 60% drop in the pVEGF only group at the same
time point. Venous catheter malfunctions prevented us from obtaining values at
Day 14 post MI in the sham animals. These data suggests that exposure of the
cardiac myocytes to GET yields minimal and transient cardiac damage.
Discussion
Insufficient myocardial oxygen delivery will result in ischemic cardiomyopathy.
This condition can, in turn, be associated with adverse cardiac remodeling and
reduced long-term survival [18]. In cases where PCI and CABG are not applicable
secondary to poor coronary artery anatomy, a novel approach, utilizing gene
transfer of angiogenic factors, may improve myocardial perfusion. In this study,
naked pVEGF was injected into the myocardium of the beating swine heart. The
injection was followed by GET in some hearts to investigate the effects of
enhancing expression of pVEGF in the ischemic and non-ischemic swine heart.
The intra-cardiac injection of pVEGF +GET increased the expression of pVEGF
compared to an injection of plasmid alone. In addition, with some GET
parameters, expression was elevated significantly in the ischemic swine heart
Fig. 7. Stroke volume. Echocardiography was used to obtain the stroke volume for pVEGF injection only,
sham and pVEGF +GET groups. A) Stroke volume before myocardial infarction, after the left anterior
descending artery (LAD) was occluded and 14 days post MI. B) Change in stroke volume at 2 weeks when
compared to pre MI baseline. C) Change in stroke volume at 2 weeks when compared to post MI baseline.
There were no statistically significant differences in SV between the groups.
doi:10.1371/journal.pone.0115235.g007
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compared to levels in the non-ischemic tissue. Expression was increased
significantly 48 hours after treatment in all but one parameter used and remained
elevated for a longer period of time than was seen with pVEGF injection alone.
SPY Intraoperative Perfusion Assessment System, was used to evaluate
fluorescent intensity as an indicator of perfusion within a specific region of the left
ventricle. Delivery of pVEGF with 20 V or 90 V did not improve fluorescent
intensity compared to IO or sham. Animals that were treated with pVEGF +GET
at 40 V were observed to have improved fluorescence intensity from an 83% drop
post MI (pretreatment) to a 33% drop 2 weeks after treatment (Table 1). We
observed that animals treated with pVEGF+ GET at 20 milliseconds at 60 V
exhibited the largest improvement in fluorescent intensity 2 weeks after treatment.
The decrease in fluorescent intensity improved from an 87% drop to only a 19%
drop. This change in fluorescent intensity after two weeks correlates with a
significant (p,0.03) increase in coronary blood flow in animals treated with
pVEGF +GET at 60 V, when compared to the IO or sham treated animals. This
finding suggests that angiogenesis may be occurring. To confirm that the
increased perfusion was related to angiogenesis, it would have been useful to have
sectioned the ischemic tissue and performed immunostaining for angiogenic
markers (i.e. CD31). Unfortunately, the samples were homogenized to perform
the ELISAs to determine the expression levels of VEGF. Therefore, the ability to
do histological analysis on the samples was lost. Now that there is evidence that
the level of perfusion in the ischemic swine heart can be influenced, future plans
are to do a more comprehensive study that would include histological analysis.
We used parasternal short axis left ventricular M mode echocardiographic
recordings to assess aspects of left ventricular function and structure [19]. M
mode echocardiographic measurements of left ventricular function are reported
to be less accurate than hemo-dynamically derived estimations [20, 21]. However,
others have found a good correlation between angiographic and echocardio-
graphic left ventricular dimensions and functions [22, 23].
Analysis of the changes in LVEDV and LVESV, using the newly established post
MI baseline values shortly after occlusion of the LAD indicated a 31% increase in
LVEDV, which was associated with a 71% increase in LVESV in the IO group.
There was a 20% decrease in LVEDV and a 67% decrease in LVESV in the sham
group. In the plasmid +GET group of animals, we observed a 29% increase in
LVEDV, which was associated with a 13% increase in LVESV. We speculate that
these data may suggest a problem with diastolic filling in the IO and sham treated
animals. In the IO animals, an increase in preload to the left ventricle (LVEDV)
was not associated with the expected decrease in LVESV. In fact, LVESV actually
Fig. 8. Left ventricular end diastolic volume. Echocardiography was used to obtain left ventricular end
diastolic volume (LVEDV) for pVEGF injection only, sham and pVEGF +GET groups. A) LVEDV before
myocardial infarction, after the left anterior descending artery (LAD) was occluded and 14 days post MI. B)
Change in LVEDV at 2 weeks when compared to pre MI baseline. C) Change in LVEDV at 2 weeks when
compared to post MI baseline. There were no statistically significant differences in LVEDV between the groups.
doi:10.1371/journal.pone.0115235.g008
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trended upward. In the sham group, preload decreased as did LVESV, suggesting a
possible alteration in filling of the left ventricle.
We speculate that a loss of compliance, or stiffening of the left ventricle after
ischemia, was greater in the hearts treated with plasmid only or saline as evidenced
by the relationships exhibited between LVEDV and LVESV. Conditions such as
myocardial infarction can cause the heart muscle to enlarge abnormally and/or
become stiff [24]. A stiffened left ventricle would make the filling process during
diastole less efficient and could have led to the decrease in LVEDV observed in the
sham animals 2 weeks post MI. It should be remembered that this group of
animals had a 46% increase in EF 2 weeks post MI. Therefore, the high EF in the
sham group may be due to improper or reduced filling of the chamber, which
forced the ventricle to pump a higher fraction of the total amount of blood
entering it. This decreased left ventricular blood volume remaining in the
chamber would necessitate an increase in EF to maintain cardiac output.
The increased EF in this group may reflect a greater percent of the reduced
volume being pumped out of the left ventricle. In the plasmid +GET group, the
increase in preload was accompanied by a smaller increase in LVESV, suggesting
that contractility of the left ventricle was more efficient than in the other two
groups. It is possible for damage to the left ventricle, which is a major pumping
chamber, to occur without an abnormal ejection fraction [25]. Hence, the plasmid
+GET treated animals may have had a more compliant left ventricle. There was a
Fig. 9. Left ventricular end systolic volume. Echocardiography was used to obtain left ventricular end
systolic volume (LVESV) for pVEGF injection only, sham and pVEGF +GET groups. A) LVESV before
myocardial infarction, after the left anterior descending artery (LAD) was occluded and 14 days post MI. B)
Change in LVESV at 2 weeks when compared to pre MI baseline. C) Change in LVESV at 2 weeks when
compared to post MI baseline. There were no statistically significant differences in LVESV between the groups.
doi:10.1371/journal.pone.0115235.g009
Table 2. Plasma troponin and creatine kinase measurements before and after occlusion of the LAD coronary artery.
Plasma Troponin Creatine Kinase
Time








Pre MI 3.52¡3.3 (ng/ml) 1.8¡1.7 (ng/ml) 4.0¡5.2 (ng/
ml)
Pre MI 409¡289 (ng/ml) 456¡408 (ng/ml) 696¡206 (ng/
ml)
Post MI 59¡42 26¡23 31¡16 Post MI 2210¡1604 2521¡305 1363¡348
1 hour 31¡35 9.6¡11 21¡8 1 hour 3682¡1968 4740¡2338 2187¡273
3 hours 157¡124 140¡151 133¡90 3 hours 4488¡2038 7289¡3926 5246¡1093
1 day 6772¡2396* 3339¡1295 3980¡1600 1 day 4361¡122 9202¡4610 6776¡5143
2 days 5789¡2873# 2144¡347 2259¡1232 2 days 5072¡4759 3235¡1975 1498¡1022
4 days 1024¡1117 369¡53 554¡37 4 days 538¡238 429¡63
14 days 10.7¡0 11.9¡0 14 days 420¡106 1004¡408
Enzyme values immediately after LAD occlusion was used as the baseline value. Data stated as mean ¡ SD.
*p,0.02 pVEGF+GET (20 milliseconds; 60 Volts) 1 day post operatively versus pVEGF injection only or Sham.
#p,0.009 pVEGF+GET (20 milliseconds; 60 Volts) 2 days post operatively versus pVEGF injection only or Sham.
doi:10.1371/journal.pone.0115235.t002
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2.2 L/min increase in CO in the plasmid +GET group compared to the 0.71 L/min
increase in the IO group and to the 0.9 L/min increase in the sham group two
weeks post infarction. The plasmid +GET hearts were able to increase HR by
60 bpm and SV by 6.5 ml to sustain this CO. However, HR only increased by
40 bpm and SV by 1.35 ml in the IO group, and by 45.5 bpm and 2.0 ml,
respectively, in the sham group. These data suggest reasons for the relatively low
CO in the IO and sham groups, although EF was either within normal range (IO
group) or high range in the sham group. We have not attempted to make any
functional statements regarding these data. However, collectively they may suggest
that left ventricular compliance is less in the sham and IO groups than in the
group treated with pVEGF +GET.
Changes in cardiac output were supported by the changes in intensity of
fluorescence, corresponding to an increase in perfusion. As measured by the SPY
System pVEGF +GET (20 ms; 60 V), treated hearts had a greater improvement in
fluorescence intensity 14 days post MI than did the IO or sham groups. The
improvement in fluorescent intensity in the pVEGF +GET (20 ms; 60 V) treated
hearts was 55% greater than in the no treatment group, and 62% greater than in
the pVEGF injection only group, suggesting that perfusion was enhanced.
In summary, we have demonstrated that GET enhances the expression of
pVEGF and the expression can be maintained for at least 14 days. In addition,
delivery and subsequent expression of pVEGF is associated with a greater
improvement in fluorescent intensity (coronary perfusion) of the ischemic
myocardium in the swine heart.
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